IUI Success Rates by Age — What to Expect Per Cycle

Intrauterine insemination (IUI) is one of the most common fertility treatments in the world — minimally invasive, relatively affordable, and appropriate for a wide range of diagnoses. It also has success rates that are frequently misunderstood.

Per-cycle success rates for IUI are modest: typically 8–20% per cycle depending on age, diagnosis, and whether ovarian stimulation is used. That number surprises many patients who expected higher odds. But cumulative rates across multiple cycles are meaningfully better — and the right comparison point is not "IUI vs. nothing" but "IUI vs. timed intercourse with or without treatment."

This guide covers what the evidence actually shows about IUI success rates, what factors influence outcomes, how to read the cumulative data, and when the evidence supports moving from IUI to IVF.

What Is IUI?

Intrauterine insemination involves placing washed, prepared sperm directly into the uterus using a thin, flexible catheter — bypassing the cervix and depositing sperm close to the fallopian tubes where fertilization occurs.

IUI is typically timed to coincide with ovulation — either natural ovulation (identified by LH surge monitoring) or ovulation triggered after pharmaceutical stimulation of the ovaries. The procedure itself takes minutes in a clinic and is generally described as feeling similar to a Pap smear.

The key distinction from natural intercourse is that IUI:

1. Places more sperm closer to the egg (bypasses cervical mucus filtering)
2. Can be timed precisely to ovulation
3. Uses washed sperm (selecting the motile fraction)
4. Can be combined with ovarian stimulation to increase the number of available eggs

Per-Cycle IUI Success Rates by Age

Per-cycle IUI success rates — expressed as live birth rate or clinical pregnancy rate — vary primarily by:

• Female age (the dominant variable)
• Whether ovarian stimulation is used
• Underlying diagnosis

Natural Cycle IUI (No Ovarian Stimulation)

Stimulated IUI (with Letrozole, Clomiphene, or Gonadotropins)

Adding ovarian stimulation increases the number of mature follicles, which raises success rates:

These figures are consistent with ASRM IUI practice committee guidelines and published data from large prospective studies including Guzick et al. (NEJM, 1999) and Bhattacharya et al. (BMJ, 2008).

Cumulative IUI Success Rates After 3–6 Cycles

The per-cycle rates above look modest, but they compound across multiple cycles. If each cycle has a 12% clinical pregnancy rate (stimulated IUI, woman under 35), the cumulative probability across 3 cycles is approximately:

• After 1 cycle: ~12%
• After 2 cycles: ~23%
• After 3 cycles: ~32%
• After 4 cycles: ~40%
• After 6 cycles: ~53%

(Calculated as: 1 - (1 - per cycle rate)^n)

Most reproductive endocrinologists recommend completing 3–4 IUI cycles before reassessing, because the cumulative success across those cycles represents a meaningful probability of conception in appropriate candidates. Success rates in subsequent cycles (beyond 4) tend to decline, suggesting that patients who have not succeeded in 3–4 cycles may have factors that IUI cannot overcome.

Does IUI Actually Work Better Than Timed Intercourse?

This is an important question that the evidence addresses directly. Bhattacharya et al. (BMJ 2008) conducted a randomized controlled trial comparing:

1. Unstimulated IUI
2. Clomiphene-stimulated IUI
3. Expectant management (timed intercourse with monitoring)

The finding: stimulated IUI did not significantly outperform timed intercourse with clomiphene in terms of live birth rates for unexplained infertility. Unstimulated IUI was slightly inferior to the other two arms.

However, this trial applied to couples with unexplained infertility who were under 40 and had been trying for less than 3 years. The findings may not apply to:

• Male factor infertility (where IUI's cervical bypass provides clear benefit)
• Cervical factor infertility
• Couples using donor sperm
• Older patients for whom time pressure changes the calculus

Guzick et al. (NEJM 1999) showed that IUI combined with superovulation significantly outperformed IUI alone and timed intercourse with superovulation. The combination of both interventions — sperm delivery and enhanced ovulation — produced the best outcomes.

The practical takeaway: IUI is most clearly beneficial when combined with ovarian stimulation, and most clearly differentiated from timed intercourse in cases of mild male factor, cervical factor, or donor sperm use.

IUI Success Rates by Diagnosis

Unexplained Infertility

For unexplained infertility, stimulated IUI is a reasonable first-line treatment. ASRM guidelines support 3–4 cycles before moving to IVF. Success rates are in the ranges described above.

Mild Male Factor

IUI bypasses the cervix and concentrates the motile fraction, both of which benefit mild male factor infertility. A total motile count (TMC) of at least 5–10 million in the washed sample is generally considered the threshold for IUI viability. Below 5 million TMC, IVF with ICSI is typically recommended.

Cervical Factor

When the cervical mucus is inhospitable to sperm (due to cervical stenosis, prior cervical procedures, or abnormal mucus), IUI bypasses the cervix entirely, which is its primary benefit in this indication.

Donor Sperm

IUI with donor sperm is a common and effective approach for single women, same-sex female couples, or couples where severe male factor or genetic concerns preclude use of partner sperm. Success rates with donor sperm are generally slightly higher than with partner sperm, reflecting the high quality of screened donor specimens.

Ovulatory Dysfunction (PCOS, Irregular Cycles)

IUI combined with ovulation induction is highly effective for ovulatory dysfunction. Women with PCOS in particular benefit from letrozole-stimulated IUI. Since the underlying problem is irregular or absent ovulation — not a sperm or anatomical issue — inducing ovulation and timing IUI produces good results.

Tubal Factor

IUI is not appropriate when there is bilateral tubal blockage, as sperm and egg cannot meet. If one tube is open, IUI is possible but success rates are lower. IVF is the preferred treatment for tubal factor.

Trying to Conceive at Home?

If you're exploring IUI alongside home insemination options, it's worth understanding the distinction: home insemination (ICI) uses unwashed sperm placed at the cervix — a different route than clinical IUI. MakeAMom offers reusable at-home insemination kits for ICI use: the CryoBaby for frozen or low-volume sperm, the Impregnator for low-motility sperm, and the BabyMaker for those with sensitivities.

Explore home insemination kits at MakeAMom →

Stimulation Protocols for IUI

Letrozole (Aromatase Inhibitor)

Letrozole is now the preferred ovulation induction agent for most IUI cycles, particularly for women with PCOS. It works by temporarily blocking estrogen production, which stimulates the pituitary to release more FSH and drive follicular development.

Benefits:

• Lower multiple pregnancy risk than clomiphene (typically 1 dominant follicle)
• Higher live birth rate per cycle than clomiphene for PCOS (demonstrated in Legro et al., NEJM 2014)
• Does not thin the endometrial lining (a side effect of clomiphene)

Typical dose: 2.5–5 mg daily for days 3–7 of the cycle.

Clomiphene Citrate

Clomiphene is an older oral agent that works by blocking estrogen receptors, causing the pituitary to increase FSH output. It is still used but is less preferred than letrozole for most indications.

• Multiple follicle development is more common than with letrozole
• Can thin the endometrium and reduce cervical mucus, which may partially counteract its benefit
• Twin pregnancy rate with clomiphene IUI: approximately 6–8%

Injectable Gonadotropins

FSH injections (Gonal-F, Follistim, Menopur) are the most potent stimulation option for IUI. They produce multiple follicles and significantly increase IUI success rates — but also substantially increase multiple pregnancy risk.

When gonadotropin stimulation produces 3 or more mature follicles (18mm or larger), most REIs will cancel the IUI cycle or recommend conversion to IVF to avoid high-order multiple pregnancy. This is standard practice.

When to Stop IUI and Move to IVF

ASRM guidelines recommend that most patients consider transitioning from IUI to IVF after 3–4 failed IUI cycles with stimulation. The reasoning:

1. Cumulative success rates plateau after 4 cycles for most diagnoses
2. IVF offers significantly higher per-cycle success rates
3. Time is a factor, particularly for women approaching or over 38
4. Continued IUI beyond 4 cycles has diminishing returns and increasing cost per successful outcome

Specific Situations Where Earlier Escalation Makes Sense

Age over 38: The per-cycle benefit of IUI relative to IVF is narrower in older patients. Some reproductive endocrinologists recommend going directly to IVF in women over 38–40 given the urgency imposed by egg quality decline.

Low total motile count: If the prepared IUI sample consistently has fewer than 5 million motile sperm, IVF with ICSI is more likely to succeed.

Bilateral tubal blockage: IVF is the only option.

Multiple failed IUI cycles with poor response: If ovarian stimulation consistently produces only 1 follicle and cycles continue to fail, the addition of IVF access to multiple eggs may improve chances.

PGT-A interest: IVF allows preimplantation genetic testing; IUI does not. For a direct comparison of these two treatment paths, see IUI vs. IVF — which is right for you?.

Cost of IUI

Understanding cost per success — not just cost per cycle — is important for treatment planning.

Compared to IVF ($15,000–$25,000 per cycle), IUI appears far more affordable per cycle. However, when you calculate cost per live birth — accounting for IUI's lower per-cycle success rate — the cost efficiency advantage of IUI narrows, particularly in older patients or those who require many cycles.

Frequently Asked Questions

Q: What are realistic IUI success rates per cycle? A: Per-cycle clinical pregnancy rates for IUI depend primarily on age and whether ovarian stimulation is used. For natural cycle IUI without stimulation, rates are approximately 8–12% under age 35, 6–10% at 35–37, and 4–7% at 38–40. Adding ovarian stimulation (letrozole, clomiphene, or gonadotropins) improves these rates to approximately 12–20% under 35 and 10–15% at 35–37. These figures are consistent with ASRM practice committee guidelines and large prospective studies including Guzick et al. (NEJM, 1999) and Bhattacharya et al. (BMJ, 2008).

Q: Does IUI work better than timed intercourse? A: The Bhattacharya et al. (BMJ 2008) randomized controlled trial found that stimulated IUI did not significantly outperform timed intercourse with clomiphene in live birth rates for unexplained infertility in couples under 40. However, IUI is most clearly beneficial over intercourse when combined with ovarian stimulation, and when there is mild male factor, cervical factor, or donor sperm use — where IUI's cervical bypass and sperm concentration provide direct advantages. Guzick et al. (NEJM 1999) demonstrated that IUI combined with superovulation significantly outperformed either intervention alone.

Q: How many IUI cycles should be attempted before moving to IVF? A: ASRM guidelines recommend that most patients consider transitioning from IUI to IVF after 3–4 failed IUI cycles with stimulation. Cumulative success rates plateau after 4 cycles for most diagnoses, IVF offers significantly higher per-cycle rates, and continued IUI beyond 4 cycles has diminishing returns. Earlier escalation to IVF is appropriate for women over 38, when prepared IUI samples consistently have fewer than 5 million motile sperm, or when PGT-A genetic testing is needed.

Q: Why is letrozole preferred over clomiphene for stimulated IUI? A: Letrozole has a lower multiple pregnancy risk than clomiphene (typically producing 1 dominant follicle rather than multiple), a higher live birth rate per cycle for PCOS (demonstrated in Legro et al., NEJM 2014), and does not thin the endometrial lining or reduce cervical mucus — both known side effects of clomiphene that can partially counteract the benefit of stimulation. Letrozole 2.5–5 mg daily for days 3–7 is now the preferred first-line ovulation induction agent for most IUI cycles.

Q: What minimum sperm quality is needed for IUI to be viable? A: A total motile count (TMC) of at least 5–10 million in the washed IUI sample is generally considered the minimum threshold for IUI viability. Below 5 million TMC, IVF with ICSI is typically recommended because the low concentration of motile sperm makes natural fertilization through the fallopian tubes unlikely even with direct uterine placement. IUI is most effective for mild male factor; severe oligospermia or severe teratospermia are better addressed with ICSI.

Key Takeaways

• IUI per-cycle success rates range from approximately 8–20% depending on age, diagnosis, and whether stimulation is used
• Cumulative rates after 3–4 cycles are meaningfully higher: approximately 30–50% for women under 38 in good circumstances
• Stimulated IUI (letrozole or gonadotropins) outperforms natural cycle IUI; letrozole is preferred for most patients due to lower multiple pregnancy risk
• Diagnosis matters: IUI is most beneficial for mild male factor, cervical factor, donor sperm use, and ovulatory dysfunction
• ASRM recommends considering IVF after 3–4 failed IUI cycles; escalate earlier for women over 38 or with low sperm counts
• IUI is not appropriate for bilateral tubal blockage, severe male factor, or situations requiring PGT-A

This article is for informational purposes only and does not constitute medical advice. Please consult a board-certified reproductive endocrinologist for personalized guidance.